P488 Exposure-response relationship of vedolizumab after 6 weeks of treatment in adults with Crohn's disease
M. Rosario, Marc R. Gastonguay(Metrum Research Group (United States)), Irving H. Fox(Takeda (United States)), JJ French(Hospital Universitario Virgen del Rocío), A. Milton, Nathanael L. Dirks(Metrum Research Group (United States))
Cited by 3
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
|Gastroenterology|2014|714
Treatment of Ulcerative Colitis with a Humanized Antibody to the α <sub>4</sub> β <sub>7</sub> Integrin
|New England Journal of Medicine|2005|694